Allergan plc is a global pharmaceutical company. It formed when Allergan Inc. merged with Actavis in 2015. Allergan makes Botox. It is also well-known for its eye care products like Refresh and Restasis. Some of its products such as Viberzi have led patients to file injury lawsuits. In July 2018, the company finalized a settlement to end hundreds of Androderm testosterone lawsuits.
Allergan plc makes pharmaceuticals, medical devices and consumer health care brands. One of Allergan’s most well-known brands is Botox.
Over the years, Allergan has acquired other companies. Some of the companies had made problematic products, such as the Seri surgical scaffold and SSRI antidepressants Celexa and Lexapro.
Allergan also faces lawsuits over some of its newer drugs, including its antidiarrheal drug, Viberzi.
In July 2018, Allergan finalized a settlement with 500 people who sued over the company’s testosterone replacement therapy, Androderm.
Allergan operates in about 100 countries. It makes many well-known brands including Botox, Linzess, Viberzi, and Lexapro and Celexa.
The company has its headquarters in Dublin, Ireland. But Allergan employs more than 17,000 employees worldwide.
Its employees are in North America, South America, Europe, the Asia Pacific, the Middle East and Africa.
In 2017, Allergan brought in just shy of $16 billion in revenues, according to a February 2018 press release by Allergan. Brent Saunders is the company’s CEO.
Allergan plc got its start as Allergan Pharmaceuticals Inc. in 1950.
Pharmacist Gavin S. Herbert founded Allergan. He created the company’s first drug alongside chemist Stanely Bly.
They called the drug Allergan. It was an antihistamine administered via the nose.
Next, came the eye drops in 1953. Eye care products were the company’s primary focus before it went public in 1970.
Allergan products include pharmaceuticals, consumer health care products and medical devices. The company specializes in products for the central nervous system, eye care, aesthetics medicine and gastroenterology.
Allergan has had to recall some of its products. Reasons include improper packaging or similar defects that could lead to patient harm.
Some of Allergan’s drugs and devices have caused patient injuries that led to lawsuits.
Product liability lawsuits filed against the company allege negligence and fraud. They say the company failed to warn of dangerous risks and promoted the drug for off-label — or unapproved — uses.
Patients injured by the testosterone replacement drug Androderm filed lawsuits against Allergan. The drug’s original maker, Actavis, is named in the testosterone lawsuits as well.
Lawsuits say patients suffered from severe and even life-threatening side effects after using Androderm. Testosterone side effects alleged in lawsuits include heart attacks, blood clots and sudden death.
Allergan agreed in 2018 to settle more than 500 cases currently pending in federal court.
Patients who suffered side effects after taking Viberzi are filing lawsuits against Allergan. They claim the antidiarrheal drug led to severe acute pancreatitis.
Some of these patients also suffered from a condition called sphincter of Oddi spasm. Two people affected by these conditions have died.
The lawsuits over Viberzi are still in the early stages. No large settlements have been announced.
Patients injured by the SSRI antidepressants Lexapro and Celexa sued Forest Laboratories. Actavis acquired Forest Laboratories before merging with Allergan Inc. to create Allergan plc.
Patients who took these medications were at a greater risk for committing suicide. Also, women who took these drugs while pregnant had babies with birth defects.
Thousands of lawsuits over Celexa and Lexapro were pending against the drug manufacturer at the height of litigation.
Forest Laboratories paid millions of dollars in verdicts and settlements. This includes more than $7 million in a class action settlement.
In 2010, Forest Laboratories also pleaded guilty to criminal charges involving the SSRIs.
The U.S. Attorney’s Office in Boston was asked to reopen a criminal case against the drug maker in early 2018. Allegations involve the misrepresentation of the drugs’ safety.
Patients implanted with Seri surgical scaffold sued Allergan after they experienced complications.
Complications of Seri surgical scaffold include tissue death, seromas, hematomas, implant loss, capsular contracture and breast infection.
In mid-2015, the FDA warned Allergan about its marketing of the silk-based surgical mesh. The company marketed the device for breast surgery, despite not having FDA approval for the use.
In 2018, Allergan reached a settlement for an undisclosed amount with a woman who accused the company of promoting the device for breast reconstruction surgery. She suffered disfigurement and required more surgeries.
Allergan acquired the Seri Scaffold technology when it purchased its original maker Serica in 2010. In 2016, Sofregen Medical purchased the product line from Allergan.
Patients injured after using Botox sued Allergan. They said the drug caused droopy eyelids, numbness, headaches, problems swallowing and breathing, brain damage, and death.
In 2010, Allergan agreed to pay $600 million to the federal government to resolve allegations of off-label promotion of the drug, according to the U.S. Department of Justice.
Jurors ordered Allergan to pay $212 million to a Virginia man who suffered brain damage after using the drug to treat hand tremors — an off-label use. It was the largest penalty ever in a Botox injury case, The Los Angeles Times reported.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(888) 645-1617